Sun Pharma’s shares fell 3 per cent after the pharmaceutical company temporarily suspended production at its Mohali facility to comply with the US Food and Drug Administration (FDA)’s regulations. The company received a letter, titled “Consent Decree Correspondence/Non-Compliance Letter”, instructing it to conduct certain corrective actions at the Mohali facility before resuming production. Sun Pharma stated that it is taking the necessary steps, but will temporarily pause the release of batches until the FDA-mandated measures have been implemented., Sun Pharma’s shares fell 3 per cent after the pharmaceutical company temporarily suspended production at its Mohali facility to comply with the US Food and Drug Administration (FDA)’s regulations. The company received a letter, titled “Consent Decree Correspondence/Non-Compliance Letter”, instructing it to conduct certain corrective actions at the Mohali facility before resuming production. Sun Pharma stated that it is taking the necessary steps, but will temporarily pause the release of batches until the FDA-mandated measures have been implemented., , Read More
AAS Yoga
Go for Euphoria – Illness to Wellness the Natural Way